Among 20 people with Graves' disease who had bulging eyes and eyelid retraction, batoclimab injections led to measurable improvements in eye appearance, with eyes receding slightly and eyelids closing more normally by 12 weeks.
Claim Context
In 20 of 25 patients with Graves' disease and mild-to-moderate Graves' orbitopathy, batoclimab treatment was associated with a mean reduction of 2.0 mm in proptosis and 1.4 mm in lid aperture by week 12.
“Eighty percent of patients (20/25) had mild-to-moderate pre-existing GO at baseline. Batoclimab was associated with improvements from baseline in proptosis (mean [SD] change: Week 12, -2.0 [1.52] mm; Week 24, -2.5 [1.75]), lid aperture (Week 12, -1.4 [1.44]; Week 24, -1.7 [1.26]), and CAS in the study eye (Week 12, -1.2 [0.98]; Week 24, -1.2 [1.1]).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether batoclimab consistently improves orbital signs in Graves' orbitopathy across multiple randomized trials, using standardized clinical scales.
A systematic review and meta-analysis of all randomized, double-blind, placebo-controlled trials of batoclimab in Graves' orbitopathy, including at least 300 participants, with primary outcomes of proptosis reduction ≥2 mm and Clinical Activity Score improvement ≥2 points at 12 weeks.
Whether batoclimab causes greater improvement in orbital signs compared to placebo in patients with active Graves' orbitopathy.
A double-blind, placebo-controlled, multicenter trial of 120 adults with Graves' orbitopathy (CAS ≥3), randomized 1:1 to batoclimab (680 mg then 340 mg weekly) or placebo for 24 weeks, with primary endpoints being proptosis reduction ≥2 mm and CAS improvement ≥2 points at week 12.
Whether orbital improvement after batoclimab is sustained over 1–2 years and correlates with reduced need for orbital radiation or surgery.
A prospective cohort study of 200 patients with Graves' orbitopathy treated with batoclimab, measuring proptosis, lid aperture, CAS, and need for orbital interventions at baseline, 6, 12, 18, and 24 months.
Whether baseline TRAb levels predict orbital response to batoclimab.
A case-control study comparing 50 patients with ≥2 mm proptosis reduction after batoclimab to 50 with minimal change, assessing baseline TRAb, orbital MRI findings, and disease duration as predictors.
The proportion of patients with Graves' orbitopathy who show orbital improvement while on batoclimab in clinical practice.
A cross-sectional survey of 300 patients with Graves' orbitopathy currently on batoclimab, measuring current proptosis, lid aperture, and CAS at a single time point.